Latest news with #PCSK9
Gulf Today
23-07-2025
- Business
- Gulf Today
AstraZeneca plans to invest $50 billion in US by 2030
AstraZeneca has announced a $50 billion investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas. WAM
Business Insider
22-07-2025
- Business
- Business Insider
AstraZeneca announces $50B of investment in U.S. by 2030
AstraZeneca (AZN) announces $50B of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5B announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. 'The $50B investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland; State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials. Our growing research and development investment in novel medicines. Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80B in Total Revenue by 2030, of which we expect 50% would be generated in the U.S.' Elevate Your Investing Strategy:
Business Wire
21-07-2025
- Business
- Business Wire
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' Governor Glenn Youngkin, Commonwealth of Virginia, said: 'I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.' Pascal Soriot, Chief Executive Officer, AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca.
Yahoo
21-07-2025
- Business
- Yahoo
AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers
AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming years. The commitment is the largest investment to-date, according to the company in a statement Monday. It includes expansions of current sites, including in Maryland and Massachusetts, as well as new facility in Virginia. "The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of the-art centre will produce small molecules, peptides and oligonucleotides," the company said. U.K.-based AstraZeneca said it currently relies on the U.S. market for 42% of its revenues, and hopes to increase the U.S. market share to 50% with this move. Its known for oncology drugs Tagrisso and Imfinzi. AstraZeneca's leadership was scheduled to speak at an event in Washington, D.C. Monday evening, flanked by Virginia Gov. Glenn Youngkin and U.S. Commerce Dept. representatives. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030," said CEO Pascal Soriot. The strategy to invest billions in manufacturing is one being deployed by the industry in order to curry favor with President Donald Trump and his re-shoring agenda, and in hopes of avoiding strict tariffs on imported drug components manufactured abroad. Some of the largest investment commitments to-date have been Johnson & Johnson's (JNJ) $55 billion announcement and Eli Lilly's (LLY) $50 billion. With a previous $3.5 billion announced in November 2024, the new $50 billion commitment puts AstraZeneca in second. Trump has promised the pharma industry will face tariffs starting August 1. Industry leaders have pleaded with the administration for more time, and Trump has hinted the tariffs could be phased-in, as the companies work to bring their manufacturing onshore. The industry has been hoping Trump would ease up on the tariffs, in exchange for the onshoring commitments. J&J CFO Joe Wolk recently told Yahoo Finance the company has met with Trump and tried to persuade him to understand that the industry can't move facilities overnight. Meanwhile, others, like Eli Lilly CEO Dave Ricks, are hoping the administration would halt tariffs on the industry altogether. Ricks previously said that if the administration wants a commitment to make generics and other low-revenue products in exchange for no tariffs, its something the industry could consider. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Business
- Yahoo
A $1.3 Billion Reason to Buy Eli Lilly Stock Now
Eli Lilly (LLY) is a pharmaceutical company that focuses on cardiometabolic health, neuroscience, oncology, and immunology. The company markets its products through brands like Jardiance, Emgality, Humalog, Mounjaro, and Trulicity. Eli Lilly was founded in 1876 and operates in 125 countries with its headquarters in Indianapolis, Indiana. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Eli Lilly has shown notable volatility in the medium term. Over the past month, the stock has gained 2.3%, however shares are down 1% in the year to date. The stock remains 21.4% below its 52-week high while registering a 13.7% slip in the past 52 weeks. Eli Lilly posted its first-quarter results back on May 1. The company reported a profit of $3.34 per adjusted share, widely missing analysts' $3.52 estimate. The company generated $12.73 billion in revenue, a significant 45% rise from the same quarter last year and beating Wall Street's $12.62 billion estimate. Revenue from Mounjaro saw a substantial rise of 113% year over year to $3.84 billion. Zepbound produced $2.31 billion revenue, registering 20.9% growth. Shares of Eli Lilly fell more than 11% on the results as investors focused on the revised guidance. The company lowered its profit forecast with adjusted EPS now expected in the range of $20.78 to $22.28 from the previous range of $22.50 to $24.00 per adjusted share. The company cites heightened acquired in-process research and development charges (IPR&D) as one of the reasons for the guidance cut. Eli Lilly has announced an agreement to acquire gene-editing company Verve Therapeutics (VERV) for $1.3 billion. This values Verve Therapeutics at $10.50 per share, reflecting a 67.5% premium to its pre-announcement closing price. The move comes as part of Eli Lilly's plans to diversify the company's operations beyond diabetes and weight-loss drugs. Eli Lilly will pay $1 billion upfront and an additional $300 million contingent upon Verve Therapeutics' ability to achieve certain clinical targets. The companies were already involved in a partnership aimed at utilizing gene-editing treatment to lower cholesterol levels in cardiovascular patients. Verve Therapeutics' gene-editing technique utilizes cutting-edge technology allowing it to execute precise one-time changes to the DNA. This can deactivate genes such as PCSK9, LPA, and ANGPTL3, contributing to high cholesterol levels. At present the company is undergoing early stage clinical trials in patients diagnosed with familial hypercholesterolemia, a genetic disorder that causes high levels of LDL cholesterol. Eli Lilly is a top-rated pharmaceutical stock with a consensus 'Strong Buy' rating from analysts. Its mean price target is $983.12, reflecting upside potential of nearly 29%. The stock is covered by 26 analysts and has received 20 'Strong Buy' ratings, two 'Moderate Buy' ratings, and four 'Hold' ratings from Wall Street. On the date of publication, Ruchi Gupta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
